FDA Approves Venetoclax Combination For Newly Diagnosed AML in Adults 75 Years or Older

The Food and Drug Administration (FDA) recently announced its approval of Venetoclax (Venclexta)  in combination with either decitabine or azacitidine (hypomethylating agents) or cytarabine (an antimetabolite) to treat adults 75 years…

Continue Reading FDA Approves Venetoclax Combination For Newly Diagnosed AML in Adults 75 Years or Older
Cancer Rates Overall Have Been Dropping But It’s Not All Good News, Report Shows
Source: Pixabay

Cancer Rates Overall Have Been Dropping But It’s Not All Good News, Report Shows

The State of Cancer in the United States A recent report posted by the American Cancer Society has indicated that cancer rates in the United States have been continuously falling over…

Continue Reading Cancer Rates Overall Have Been Dropping But It’s Not All Good News, Report Shows
A New Phase II Trial for Myelodysplastic Syndromes and Acute Myeloid Leukemia is Underway!
source: pixabay.com

A New Phase II Trial for Myelodysplastic Syndromes and Acute Myeloid Leukemia is Underway!

Myelodysplastic syndromes (MDS) is the name used to describe a group of stem cell disorders in which the body can't produce an adequate amount of platelets and blood cells. Currently,…

Continue Reading A New Phase II Trial for Myelodysplastic Syndromes and Acute Myeloid Leukemia is Underway!
FDA Approves Pfizer’s Acute Myeloid Leukemia Treatment for High-Risk Patients
Source: https://pixabay.com/en/thumb-up-like-sign-hand-ok-good-441938/

FDA Approves Pfizer’s Acute Myeloid Leukemia Treatment for High-Risk Patients

According to a publication from MarketScreener, pharmaceutical titan Pfizer Inc. has gained FDA approval for Daurismo, a once-a-day oral medication designed to be paired with low-dose cytarabine (a type of…

Continue Reading FDA Approves Pfizer’s Acute Myeloid Leukemia Treatment for High-Risk Patients
Rare Blood Cancer Trial Data to be Presented in Upcoming Conference
allinonemovie / Pixabay

Rare Blood Cancer Trial Data to be Presented in Upcoming Conference

According to a story from investors.amgen.com, the drug developer Amgen recently announced its intent to present all new clinical trial data which will feature its latest work in testing a…

Continue Reading Rare Blood Cancer Trial Data to be Presented in Upcoming Conference
Four New Drugs Accepted by the Scottish Medicines Consortium
qimono / Pixabay

Four New Drugs Accepted by the Scottish Medicines Consortium

The Scottish Medicines Consortium, a committee that advises NHS Scotland on what medicines they should provide, has accepted four new drugs for use. These are gemtuzumab ozogamicin for acute myeloid…

Continue Reading Four New Drugs Accepted by the Scottish Medicines Consortium
Multiple Studies Help Define New Biomarkers for Myelodysplastic Syndromes
luvqs / Pixabay

Multiple Studies Help Define New Biomarkers for Myelodysplastic Syndromes

According to a story from Medpage Today, three recent research studies have managed to reveal new biomarkers for myelodysplastic syndromes. Biomarkers are a crucial factor for understanding a medical condition…

Continue Reading Multiple Studies Help Define New Biomarkers for Myelodysplastic Syndromes

A Study of an Investigational Acute Myeloid Leukaemia and Myelodysplastic Syndrome Drug Has Completed Enrolment

  The company Imago Biosciences, which focuses on developing anti-cancer therapies, is carrying out a Phase 1/2a clinical study of an investigational drug called IMG-7289 as a potential treatment for…

Continue Reading A Study of an Investigational Acute Myeloid Leukaemia and Myelodysplastic Syndrome Drug Has Completed Enrolment

A Drug Being Developed to Treat Acute Myeloid Leukaemia Has Been Given a Generic Drug Name

The United States Adopted Name Council, which selects simple, new, and informative generic drug names, has approved ‘Onvansertib’ as the generic name for PCM-075. PCM-075 is an investigational drug that…

Continue Reading A Drug Being Developed to Treat Acute Myeloid Leukaemia Has Been Given a Generic Drug Name

Two Companies Are Collaborating to Develop a Combination Therapy For Acute Myeloid Leukaemia

Two companies, Tolero Pharmaceuticals Inc. and AbbieVie, have agreed to collaborate to clinically research a potential combination therapy for relapsed or refractory acute myeloid leukaemia. The potential therapy is comprised…

Continue Reading Two Companies Are Collaborating to Develop a Combination Therapy For Acute Myeloid Leukaemia

The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  A Biologics License Application for ElzonrisTM (also known as tagraxofusp and SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm has been accepted for filing by the United States FDA.…

Continue Reading The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Supplemental New Drug Application Submitted For Potential Acute Myeloid Leukemia Treatment
Source: Pixabay

Supplemental New Drug Application Submitted For Potential Acute Myeloid Leukemia Treatment

According to a story from PR Newswire, the biopharmaceutical company AbbVie has recently announced that it has sent a supplemental New Drug Application to the FDA for its product venetoclax,…

Continue Reading Supplemental New Drug Application Submitted For Potential Acute Myeloid Leukemia Treatment